Blue Earth patents expiration
1. Axumin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5808146 | BLUE EARTH | Amino acid analogs for tumor imaging |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10953112 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(2 years from now) | |
| US10010632 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(2 years from now) | |
| US9387266 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(2 years from now) | |
| US10716868 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10124079 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10967077 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10933147 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Method of diagnosing tumors using positron emission tomography; Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate speci...
Dosage: SOLUTION;INTRAVENOUS
AXUMIN family patents
2. Posluma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11413360 | BLUE EARTH | Dual mode radiotracer and—therapeutics |
Nov, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen...
Dosage: SOLUTION;INTRAVENOUS
POSLUMA family patents